History
# Registration date Revision Id
2 2021-02-20, 1399/12/02 173935
1 2019-03-15, 1397/12/24 83614
Changes made to previous revision
  • Help:

    Red color represents old content. It may be empty showing addition in the new version.
    Green color represents new content. It may be empty showing deletion in the new version.

    Inline Side by side
    Added new contents, deleted old contents, contents that are not changed.
    New table contents New table contents
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    Added new contents, contents that are not changed.
    Deleted old contents, contents that are not changed.
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    New table contents New table contents
    Unchanged contents Unchanged contents
  • Protocol summary

    In this clinical trial, patients with burn admitted to Motahari hospital will be included if they met the inclusion criteria. After obtaining a written consent, patients will be randomly divided to three groups to receive collagen alone (45 g daily), collagen plus fish oil (45 g daily plus 12 ml fish oil) and control (placebo with similar characteristics). In each group, 22 patients will receive the supplements for 4 weeks. The participants and main investigators will not be aware of the contents of the supplement and placebo. An individualized nutrition program will be provided for each patient. At the beginning, and at the end of weeks 2 and 4, a 10cc fasting blood sample will be taken. The levels of inflammatory and nutritional factors, anthropometric measurements, and clinical outcomes, including wound healing and hospitalization time, will be examined.
    In this clinical trial, patients with burn admitted to Motahari hospital will be included if they met the inclusion criteria. After obtaining a written consent, patients will be randomly divided to three groups to receive collagen alone (40 g daily), collagen plus fish oil (40 g daily plus 10 ml fish oil) and control (placebo with similar characteristics). In each group, 22 patients will receive the supplements for 4 weeks. The participants and main investigators will not be aware of the contents of the supplement and placebo. An individualized nutrition program will be provided for each patient. At the beginning, and at the end of weeks 2 and 3, a 10cc fasting blood sample will be taken. The levels of inflammatory and nutritional factors, anthropometric measurements, and clinical outcomes, including wound healing and hospitalization time, will be examined.
    در این کارآزمایی بالینی، بیماران دچار سوختگی پذیرش شده در بیمارستان مطهری دارای معیارهای ورود و پس از اخذ رضایت نامه کتبی به طور تصادفی به سه گروه دریافت کننده کلاژن به تنهایی (45 گرم روزانه)، کلاژن به همراه روغن ماهی (45 گرم روزانه به همراه 12 میلی لیتر روغن ماهی) و کنترل (دارونما دارای ویژگی های مشابه) تقسیم خواهند شد. در هر گروه ۲۲ بیمار برای 4 هفته این درمان مکمل تغذیه ای را دریافت خواهند کرد. افراد شرکت کننده و محقق اصلی از محتوی مکمل و دارونما اطلاعی نخواهند داشت. برنامه تغذیه ای اختصاصی برای هر فرد تنظیم می شود. در ابتدای مطالعه، پایان هفته 2 و 4، 10cc نمونه خون ناشتا از بیماران گرفته می شود و سطح فاکتورهای خونی مانند عوامل التهابی و تغذیه ای، به همراه اندازه گیری های تن سنجی، و نتایج بالینی از جمله بهبود زخم و زمان بستری مورد بررسی قرار می گیرد.
    در این کارآزمایی بالینی، بیماران دچار سوختگی پذیرش شده در بیمارستان مطهری دارای معیارهای ورود و پس از اخذ رضایت نامه کتبی به طور تصادفی به سه گروه دریافت کننده کلاژن به تنهایی (40 گرم روزانه)، کلاژن به همراه روغن ماهی (40 گرم روزانه به همراه 10 میلی لیتر روغن ماهی) و کنترل (دارونما دارای ویژگی های مشابه) تقسیم خواهند شد. در هر گروه ۲۲ بیمار برای 4 هفته این درمان مکمل تغذیه ای را دریافت خواهند کرد. افراد شرکت کننده و محقق اصلی از محتوی مکمل و دارونما اطلاعی نخواهند داشت. برنامه تغذیه ای اختصاصی برای هر فرد تنظیم می شود. در ابتدای مطالعه، پایان هفته 2 و 3، 10cc نمونه خون ناشتا از بیماران گرفته می شود و سطح فاکتورهای خونی مانند عوامل التهابی و تغذیه ای، به همراه اندازه گیری های تن سنجی، و نتایج بالینی از جمله بهبود زخم و زمان بستری مورد بررسی قرار می گیرد.
  • General information

    empty
    Change in the timing of the measurement of blood parameters is due to limitations and difficulties of visiting patients due to the prevalence of Covid 19. The change in the total amount of supplements is only due to the higher purity of the components, provided for this trial, and the amount of active ingredients (hydrolyzed collagen and omega-3 fatty acids) has not been changed. Adding new secondary outcomes (FGF21, NRG4, and VSS) is thanks to receiving more funding.
    empty
    تغییر زمان بندی اندازه گیری فاکتورهای خونی، به علت محدودیت و مشکلات مراجعات بیماران به علت شیوع کووید ۱۹ می باشد. تغییر میزان تام مکمل ها صرفا به علت خلوص بالاتر ترکیبات مواد تهیه شده برای این کارآزمایی بوده و میزان ماده موثره مورد نظر (کلاژن هیدرولیز شده و چربی های امگا-۳) تغییری نداشته است. افزودن پیامدهای ثانویه جدید (FGF21، NRG4 و VSS) به علت دریافت منابع مالی بیشتر می باشد.
  • Primary outcomes

    #1
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
  • Secondary outcomes

    #1
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #2
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #3
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #4
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #5
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #6
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #7
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #8
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #9
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #10
    Baseline, end of weeks 2 and 4
    Baseline, end of weeks 2 and 3
    ابتدا، پایان هفته 2 و 4
    ابتدا، پایان هفته 2 و 3
    #11
    empty
    Fibroblast growth factor 21 serum concentration
    empty
    سطوح سرمی فاکتور رشد فیبروبلاست 21
    empty
    Baseline, end of weeks 2 and 3
    empty
    ابتدا، پایان هفته 2 و 3
    empty
    ELISA
    empty
    الایزا
    #12
    empty
    Neuregulin 4 serum concentration
    empty
    سطوح سرمی نورگیولین 4
    empty
    Baseline, end of weeks 2 and 3
    empty
    ابتدا، پایان هفته 2 و 3
    empty
    ELISA
    empty
    الایزا
    #13
    empty
    Vancouver Scar Scale
    empty
    مقیاس اسکار ونکوور
    empty
    End of week 4
    empty
    پایان هفته 4
    empty
    Scoring based on a questionnaire
    empty
    امتیازدهی بر اساس پرسشنامه
  • Intervention groups

    #1
    Intervention group 1: Daily intake of 45 gr hydrolyzed collagen for 4 weeks
    Intervention group 1: Daily intake of 40 gr hydrolyzed collagen for 4 weeks
    گروه مداخله اول: دریافت روزانه 45 گرم کلاژن هیدرولیز شده برای 4 هفته
    گروه مداخله اول: دریافت روزانه 40 گرم کلاژن هیدرولیز شده برای 4 هفته
    #2
    Intervention group 2: Daily intake of 45 gr hydrolyzed collagen plus 12 ml fish oil for 4 weeks
    Intervention group 2: Daily intake of 40 gr hydrolyzed collagen plus 10 ml fish oil for 4 weeks
    گروه مداخله دوم: دریافت روزانه 45 گرم کلاژن هیدرولیز شده و 12 میلی لیتر روغن ماهی برای 4 هفته
    گروه مداخله دوم: دریافت روزانه 40 گرم کلاژن هیدرولیز شده و 10 میلی لیتر روغن ماهی برای 4 هفته
  • Recruitment centers

    #1
    Name of recruitment center - English: Motahari hospital
    Name of recruitment center - Persian: بیمارستان مطهری
    Full name of responsible person - English: Mostafa Dehmardei
    Full name of responsible person - Persian: مصطفی ده مرده ئی
    Street address - English: Shahid Motahari hospital, Rashid Yasemi St., Vali Asr avenue, Tehran
    Street address - Persian: تهران، خیابان ولیعصر، خیابان رشید یاسمی، بیمارستان شهید مطهری
    City - English: Tehran
    City - Persian: تهران
    Province: Tehran
    Country: Iran (Islamic Republic of)
    Postal code: ۱۴۴۹۶۱۴۵۳۵
    Phone: +98 21 8877 0031
    Fax:
    Email: hospital.motahari@yahoo.com
    Web page address:
    Name of recruitment center - English: Motahari hospital
    Name of recruitment center - Persian: بیمارستان مطهری
    Full name of responsible person - English: Mostafa Dehmardei
    Full name of responsible person - Persian: مصطفی ده مرده ئی
    Street address - English: Shahid Motahari hospital, Rashid Yasemi St., Vali Asr avenue, Tehran
    Street address - Persian: تهران، خیابان ولیعصر، خیابان رشید یاسمی، بیمارستان شهید مطهری
    City - English: Tehran
    City - Persian: تهران
    Province: Tehran
    Country: Iran (Islamic Republic of)
    Postal code: 1449614535
    Phone: +98 21 8877 0031
    Fax:
    Email: hospital.motahari@yahoo.com
    Web page address:
  • Sponsors / Funding sources

    #1

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Dr. Seyed AliJavad Mousavi
    Full name of responsible person - Persian: دکتر سید علی جواد موسوی
    Street address - English: Iran university of medical sciences, next to Milad tower, Hemmat Highway, Tehran
    Street address - Persian: تهران، بزرگراه همت، جنب برج میلاد، دانشگاه علوم پزشکی ایران
    City - English: Tehran
    City - Persian: تهران
    Province: Tehran
    Country: Iran (Islamic Republic of)
    Postal code: ۱۴۴۹۶۱۴۵۳۵
    Phone: +98 21 86701
    Fax:
    Email: adminsite@iums.ac.ir
    Web page address:

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Dr. Seyed AliJavad Mousavi
    Full name of responsible person - Persian: دکتر سید علی جواد موسوی
    Street address - English: Iran university of medical sciences, next to Milad tower, Hemmat Highway, Tehran
    Street address - Persian: تهران، بزرگراه همت، جنب برج میلاد، دانشگاه علوم پزشکی ایران
    City - English: Tehran
    City - Persian: تهران
    Province: Tehran
    Country: Iran (Islamic Republic of)
    Postal code: 1449614535
    Phone: +98 21 86701
    Fax:
    Email: adminsite@iums.ac.ir
    Web page address:

Protocol summary

Study aim
Investigating the effect of hydrolyzed collagen alone or in combination with fish oil on wound healing, metabolic disorders, and adipose derived factors in patients with burns
Design
A randomized, double-blind, parallel design clinical trial, with two intervention groups (collagen alone and collagen plus fish oil) and a control group
Settings and conduct
In this clinical trial, patients with burn admitted to Motahari hospital will be included if they met the inclusion criteria. After obtaining a written consent, patients will be randomly divided to three groups to receive collagen alone (40 g daily), collagen plus fish oil (40 g daily plus 10 ml fish oil) and control (placebo with similar characteristics). In each group, 22 patients will receive the supplements for 4 weeks. The participants and main investigators will not be aware of the contents of the supplement and placebo. An individualized nutrition program will be provided for each patient. At the beginning, and at the end of weeks 2 and 3, a 10cc fasting blood sample will be taken. The levels of inflammatory and nutritional factors, anthropometric measurements, and clinical outcomes, including wound healing and hospitalization time, will be examined.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Burns of 20-45% of body surface area and degree 2 (deep) or 3, age 18-60 year, and the ability to oral intake of foods. Non-inclusion criteria: History of any metabolic or chronic diseases, such as diabetes and organ failures, BMI<18.5 kg/m2, allergy or intolerance to protein products, pregnant women, and addicts.
Intervention groups
The protein supplement of hydrolyzed collagen will be given to patients with burn alone or with fish oil that contains essential fatty acids. The control group will receive a placebo with the same characteristics.
Main outcome variables
Pre-albumin serum levels

General information

Reason for update
Change in the timing of the measurement of blood parameters is due to limitations and difficulties of visiting patients due to the prevalence of Covid 19. The change in the total amount of supplements is only due to the higher purity of the components, provided for this trial, and the amount of active ingredients (hydrolyzed collagen and omega-3 fatty acids) has not been changed. Adding new secondary outcomes (FGF21, NRG4, and VSS) is thanks to receiving more funding.
Acronym
-
IRCT registration information
IRCT registration number: IRCT20090901002394N42
Registration date: 2019-03-15, 1397/12/24
Registration timing: prospective

Last update: 2021-03-06, 1399/12/16
Update count: 1
Registration date
2019-03-15, 1397/12/24
Registrant information
Name
Shima Jazayeri
Name of organization / entity
Iran University of Medical Sciences
Country
Iran (Islamic Republic of)
Phone
+98 21 8670 4805
Email address
sjazayeri@razi.tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2019-04-04, 1398/01/15
Expected recruitment end date
2019-12-21, 1398/09/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Effect of hydrolyzed collagen alone, or in combination with fish oil on wound healing, metabolic disorders and adipose derived peptides in patients with burn
Public title
Effect of collagen and fish oil in burn
Purpose
Supportive
Inclusion/Exclusion criteria
Inclusion criteria:
Patients with 20-45% total body surface area burn Patients with burn degree of 2 (deep) or 3 Age 18-60 years The ability of oral intake of foods
Exclusion criteria:
History of any metabolic or chronic diseases such as diabetes, cardiovascular diseases, organ failures, and etc. Body mass index < 18.5 kg/m2 History of allergy or intolerance to protein products Pregnant women Drug and alcohol addicts
Age
From 18 years old to 60 years old
Gender
Both
Phase
N/A
Groups that have been masked
  • Participant
  • Investigator
Sample size
Target sample size: 66
Randomization (investigator's opinion)
Randomized
Randomization description
For random allocation of individuals to the three groups, the permuted block randomization method will be applied, using a computer program, and the length of blocks will be considered randomly as 3, 6 or 9.
Blinding (investigator's opinion)
Double blinded
Blinding description
The participants in this study and the main investigator who will be involved in the conduction of the project will be blind to the content of supplement and placebo. The allocation of individuals and the provision of supplement and placebo will be carried out by a person independent of the research group.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics Committee of Iran University of Medical Sciences
Street address
Iran University of Medical Sciences, Hemmat Highway
City
Tehran
Province
Tehran
Postal code
1449614535
Approval date
2018-10-28, 1397/08/06
Ethics committee reference number
IR.IUMS.REC.1397.569

Health conditions studied

1

Description of health condition studied
Burns
ICD-10 code
T21
ICD-10 code description
Burn and corrosion of trunk

2

Description of health condition studied
Burns
ICD-10 code
T22
ICD-10 code description
Burn and corrosion of shoulder and upper limb, except wrist and hand

3

Description of health condition studied
Burns
ICD-10 code
T24
ICD-10 code description
Burn and corrosion of lower limb, except ankle and foot

Primary outcomes

1

Description
Pre-albumin serum concentration
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
Biochemical assay

Secondary outcomes

1

Description
Body weight
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
Body scale

2

Description
Body mass index
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
Calculation based on the relevant formula

3

Description
Duration of hospital stay
Timepoint
Time of discharge
Method of measurement
Patient's records

4

Description
Wound healing
Timepoint
End of weeks 2 and 4
Method of measurement
Observation

5

Description
High-sensitivity C-reactive Protein serum concentration
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
ELISA

6

Description
Transforming growth factor beta serum concentration
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
ELISA

7

Description
Adiponectin serum concentration
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
ELISA

8

Description
Fasting blood glucose concentration
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
Biochemical assay

9

Description
Fasting insulin serum concentration
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
ELISA

10

Description
Homeostasis model assessment of insulin resistance
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
Calculation based on the relevant formula

11

Description
Daily energy intake
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
24-h dietary recall

12

Description
Daily protein intake
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
24-h dietary recall

13

Description
Fibroblast growth factor 21 serum concentration
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
ELISA

14

Description
Neuregulin 4 serum concentration
Timepoint
Baseline, end of weeks 2 and 3
Method of measurement
ELISA

15

Description
Vancouver Scar Scale
Timepoint
End of week 4
Method of measurement
Scoring based on a questionnaire

Intervention groups

1

Description
Intervention group 1: Daily intake of 40 gr hydrolyzed collagen for 4 weeks
Category
Treatment - Other

2

Description
Intervention group 2: Daily intake of 40 gr hydrolyzed collagen plus 10 ml fish oil for 4 weeks
Category
Treatment - Other

3

Description
Control group: Placebo with same characteristics for 4 weeks
Category
Placebo

Recruitment centers

1

Recruitment center
Name of recruitment center
Motahari hospital
Full name of responsible person
Mostafa Dehmardei
Street address
Shahid Motahari hospital, Rashid Yasemi St., Vali Asr avenue, Tehran
City
Tehran
Province
Tehran
Postal code
1449614535
Phone
+98 21 8877 0031
Email
hospital.motahari@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Dr. Seyed AliJavad Mousavi
Street address
Iran university of medical sciences, next to Milad tower, Hemmat Highway, Tehran
City
Tehran
Province
Tehran
Postal code
1449614535
Phone
+98 21 86701
Email
adminsite@iums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Iran University of Medical Sciences
Proportion provided by this source
60
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

2

Sponsor
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Dr. Akbar Fotouhi
Street address
Tehran University of Medical Sciences, Ghods St., Keshavarz Blvd, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1416643931
Phone
+98 21 8895 5975
Email
office@sina.tums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
40
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Shima Jazayeri
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Iran University of Medical Sciences, Hemmat Highway
City
Tehran
Province
Tehran
Postal code
1449614535
Phone
+98 21 8670 4805
Fax
+98 21 8862 2707
Email
sjazayeri@razi.tums.ac.ir

Person responsible for scientific inquiries

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Shima Jazayeri
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Iran University of Medical Sciences, Hemmat highway, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1449614535
Phone
+98 21 8670 4805
Fax
+98 21 8862 2707
Email
sjazayeri@razi.tums.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Shima Jazayeri
Position
Associate professor
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Iran University of Medical Sciences, Hemmat Highway
City
Tehran
Province
Tehran
Postal code
1449614535
Phone
+98 21 8670 4805
Fax
+98 21 8862 2707
Email
sjazayeri@razi.tums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...